Nov. 19 at 5:31 PM
$SANA From the latest earnings report it is evident that Sana is on track.
Announced increased focus on type 1 diabetes and in vivo CAR T programs
Regulatory interactions increase confidence in moving forward with GMP master cell bank for SC451, nonclinical testing plan, and path to filing SC451 Investigational New Drug Application (IND) as early as 2026
The New England Journal of Medicine published positive 12-week clinical results of ongoing type 1 diabetes study with UP421,
which demonstrate that Sana’s hypoimmune-modified pancreatic islet cells are safe and well-tolerated, survive, evade detection by the immune system, and produce insulin in the patient
Next-generation in vivo CAR T product candidate, SG293, demonstrates deep B-cell depletion and immune reset with a single treatment in non-human primates; expect to file IND for SG293 in B-cell cancers and/or B-cell mediated autoimmune diseases as early as 2027
To focus resources on SC451 and SG293, suspended enrollment and further internal investment in allogeneic CAR T studies
Raised aggregate gross proceeds of
$115.8 million from sales of common stock through Sana’s at the market offering facility (ATM) and equity financing in the third quarter of 2025
Q3 2025 cash position of
$153.1 million and
$170.5 million pro forma cash balance including recent ATM activity; expected cash runway into late 2026
